natgillin/translations-raw huggingface dataset:
Your doctor may decide to stop your Rixathon treatment if these reactions are serious.
Zdravnik se lahko odloči za prenehanje zdravljenja z zdravilom Rixathon, če so te reakcije resne.
Rixathon will be given to you by a doctor or nurse who is experienced in the use of this treatment.
Zdravilo Rixathon vam bo dal zdravnik ali medicinska sestra, ki ima izkušnje z uporabo takšnih zdravil.
Rixathon may also cause changes in laboratory tests carried out by your doctor.
Zdravilo Rixathon lahko vpliva tudi na spremembe laboratorijskih preiskav, ki jih naroči vaš zdravnik.
• mood disorders such as irritability and depression
• spremembe razpoloženja, kot sta razdražljivost in depresija,
It remains unknown if early detection of PML and suspension of rituximab therapy may lead to similar stabilisation or improved outcome.
Ni znano, ali lahko zgodnje odkritje PML in ukinitev zdravljenja z rituksimabom doseže podobno stabilizacijo ali izboljšanje izida.
The safety and efficacy of rituximab in children below 18 years have not been established.
Varnost in učinkovitost rituksimaba pri otrocih do 18. leta starosti nista dokazani.
• Excess fluid retention in the face and body
• zadrževanje odvečne tekočine v obrazu in telesu,
Patients were followed beyond week 24 for long term endpoints, including radiographic assessment at 56 weeks and at 104 weeks.
Bolnike so od 24. tedna spremljali za dolgoročne cilje študije in naredili tudi radiološko oceno po 56 tednih ter 104 tednih.
Population pharmacokinetic analysis of the same data gave similar mean values for systemic clearance and half-life, 0.26 L/day and 20.4 days, respectively.
Populacijska farmakokinetična analiza istih podatkov je dala podobne povprečne vrednosti za sistemski očistek in razpolovni čas, 0,26 l/dan in 20,4 dni.
• ringing sound in the ears, ear pain
• zvonjenje v ušesih, bolečine v ušesu,
If you can get pregnant, you and your partner must use an effective method of contraception while using Rixathon.
Če bi lahko zanosili, morate vi in vaš partner med uporabo zdravila Rixathon uporabljati učinkovito kontracepcijsko zaščito.
• reduced platelets number just after the infusion - this can be reversed, but can be fatal in rare cases
• zmanjšanje števila trombocitov tik po infundiranju zdravila - to je mogoče odpraviti, a v redkih primerih je lahko smrtno,
Retreatment should be given at that time if residual disease activity remains, otherwise retreatment should be delayed until disease activity returns.
Ob tem času je treba bolnika ponovno zdraviti, če je bolezen še vedno aktivna, sicer pa se ponovno zdravljenje odloži, dokler bolezen spet ne postane aktivna.
1 Events were considered ADRs only after thorough assessment and where a causal relationship between the medicinal product and the adverse event was at least a reasonable possibility.
1 Dogodke so kot neželene učinke ocenili šele po natančni oceni in v primerih, v katerih je bila vzročna povezanost med zdravilom in neželenim učinkom vsaj smiselna možnost.
The transient IgM increase usually returned to at least baseline level within 4 months.
Prehodna zvišanja IgM so se običajno vrnila vsaj na raven pred zdravljenjem v 4 mesecih.
• Cardiovascular events, see section 4.4.
• kardiovaskularni dogodki, glejte poglavje 4.4.
Tell your doctor immediately if you experience any of these symptoms.
Nemudoma povejte zdravniku, če se pri vas pojavi kateri od teh simptomov.
All patients Newly diagnosed Relapsing n=99 n=48 n=51
Vsi bolniki Novoodkriti Ponovitev n = 99 n = 48 n = 51
2Details on infusion related reactions are provided in the description of selected adverse drug reactions section.
2 Podrobnosti o reakcijah, povezanih z infundiranjem, so navedene v opisu v poglavju o izbranih neželenih učinkih zdravila.
The incidence of IRR symptoms was highest during or after the first infusion (9%) and decreased with subsequent infusions (<4%).
Pojavnost simptomov IRR je bila največja med prvo infuzijo ali po njej (9 %) in se je ob nadaljnjih infuzijah zmanjšala (< 4 %).
Aseptic handling must be ensured when preparing the infusion.
Pri pripravi infuzije je treba zagotoviti aseptično rokovanje.
Severe infusion-related reactions (such as bronchospasm, hypotension) occurred in up to 12% of the cases.
Hude reakcije, povezane z infuzijo (npr. bronhospazem, hipotenzija), so se pojavile pri do 12 % bolnikov.
Rixathon in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes.
Zdravilo Rixathon v kombinaciji s kemoterapijo uniči te celice, ki se postopno odstranijo iz telesa z biološkimi procesi.
The proliferation of these abnormal B-lymphocytes is the cause of symptoms you may have.
Nastajanje teh nenormalnih limfocitov B je vzrok simptomom, ki jih morda imate.
Depending on the signs and symptoms of your disease, your doctor will decide when you should receive more Rixathon.
Glede na znake in simptome vaše bolezni se bo zdravnik odločil, kdaj boste ponovno zdravljeni z zdravilom Rixathon.
- prepared in a laminar flow hood or biological safety cabinet using standard precautions for the safe handling of intravenous agents.
- biti pripravljeno v komori z laminarnim pretokom zraka ali v biološki varnostni komori, z uporabo standardnih previdnostnih ukrepov za varno ravnanje z intravenskimi zdravili.
Very Rare Not known
Zelo redki Neznana
Patients reporting signs and symptoms of infection following Rixathon therapy should be promptly evaluated and treated appropriately.
Bolnike, pri katerih se pojavijo znaki in simptomi okužbe po zdravljenju z zdravilom Rixathon, je treba nemudoma pregledati in primerno zdraviti.
The HCP educational leaflets and the Patient educational leaflet will be agreed with the National Competent Authorities prior to distribution.
O izobraževalnih letakih za zdravstvenega delavca in izobraževalnih letakih za bolnika bo pred razdelitvijo dogovorjeno z nacionalnim organom, pristojnim za zdravila.
EULAR response (%)
Odziv po EULAR (%)
• low mood and loss of interest or enjoyment in doing things, feeling nervous
• slabo razpoloženje in izguba zanimanja ali veselja za početje stvari, živčnost,
Therefore patients with a history of cardiac disease and/or cardiotoxic chemotherapy should be monitored closely.
Zato je treba bolnike z anamnezo srčne bolezni in/ali kardiotoksične kemoterapije skrbno nadzorovati.
6336 Langkampfen Austria
6336 Langkampfen AVSTRIJA
6336 Langkampfen AUSTRIA
6336 Langkampfen Avstrija
Following reconstitution of the immune system in immunocompromised patients with PML, stabilisation or improved outcome has been seen.
Po okrevanju imunskega sistema pri imunsko oslabljenih bolnikih s PML so opazili stabilizacijo ali izboljšanje izida.
The incidence of infections that were serious or required intravenous antibiotics was approximately 4 per 100 patient years.
Incidenca okužb, ki so bile resne ali so zahtevale uporabo intravenskega antibiotika, je bila približno 4 na 100 bolnik-let.
The most frequently reported events were tachycardia (4%) and atrial fibrillation (3%) (see section 4.4).
Najpogosteje opisana neželena učinka sta bila tahikardija (4 %) in atrijska fibrilacija (3 %) (glejte poglavje 4.4).
The alert card contains important safety information for patients regarding potential increased risk of infections, including progressive multifocal leukoencephalopathy (PML).
Opozorilna kartica vsebuje za bolnika pomembne podatke o varnosti glede možnega povečanega tveganja za okužbe, vključno s progresivno multifokalno levkoencefalopatijo (PML).
Before you are given Rixathon you will be given other medicines (premedication) to prevent or reduce possible side effects.
Preden boste dobili zdravilo Rixathon, boste dobili druga zdravila (to imenujemo premedikacija) za preprečitev ali zmanjšanje možnih neželenih učinkov.
• tremors (shakiness, often in the hands)
• tremor (tresenje, pogosto tresenje rok),
• painful joints or back
• boleči sklepi ali hrbet,
38 months
38 mesecev NR
Rarely Rixathon can cause a serious brain infection, called “Progressive Multifocal Leukoencephalopathy” or PML.
Redko lahko zdravilo Rixathon povzroči resno možgansko okužbo, imenovano progresivna multifokalna levkoencefalopatija ali PML.
For these reasons Rixathon should not be administered to pregnant women unless the possible benefit outweighs the potential risk.
Zato nosečnice ne smejo prejemati zdravila Rixathon, razen če je pričakovana korist večja od možnega tveganja.
Prednisone treatment was tapered and then kept at a low dose (approximately 5 mg per day) for at least 18 months after randomization.
Zdravljenje s prednizonom so postopoma zmanjšali in ga nato vzdrževali v majhnem odmerku (približno 5 mg na dan) vsaj 18 mesecev po randomizaciji.
In clinical trials more than 3,100 patients received at least one treatment course and were followed for periods ranging from 6 months to over 5 years; approximately 2,400 patients received two or more courses of treatment with over 1,000 having received 5 or more courses.
V kliničnih preskušanjih je več kot 3.100 bolnikov prejelo najmanj en cikel zdravljenja, po tem so jih spremljali od 6 mesecev do več kot 5 let; približno 2.400 bolnikov je prejelo dva ali več ciklov zdravljenja, od teh pa več kot 1.000 bolnikov 5 ali več ciklov zdravljenja.
Observation N=513
Opazovanje n = 513
p-value Risk reduction1)
R-CHOP Vrednost p Zmanjšanje tveganja1)
You may be asked not to take these other medicines 12 hours before you are given Rixathon.
Morda vam bo naročil, da ne jemljite teh drugih zdravil 12 ur, preden boste dobili zdravilo Rixathon.
1 Frequency category derived from laboratory values collected as part of routine laboratory monitoring in clinical trials
1Pogostnost pridobljena iz laboratorijskih vrednosti zbranih v okviru rutinskega laboratorijskega spremljanja v kliničnih preskušanjih.
Figure 2: ACR responses for 4 treatment courses (24 weeks after each course (within patient, within visit) in patients with an inadequate response to TNF-inhibitors (n=146)
Slika 2: Odzivi ACR za 4 cikle zdravljenja 24 tednov po vsakem ciklu (intraindividualno, znotraj pregledov) pri bolnikih, ki niso zadostno odgovorili na zdravljenje z zaviralci TNF (n = 146)
Long-term efficacy with multiple course therapy
Dolgotrajna učinkovitost z več cikli zdravljenja
CD20 is found on both normal and malignant B cells, but not on haematopoietic stem cells, pro-B cells, normal plasma cells or other normal tissue.
CD20 najdemo tako na običajnih kot na malignih celicah B, vendar ne na matičnih krvotvornih celicah, pro-B-celicah, normalnih plazmatkah ali drugem normalnem tkivu.
Vaccination should be completed at least 4 weeks prior to first administration of Rixathon.
Cepljenje naj bo zaključeno najmanj 4 tedne pred prvo aplikacijo zdravila Rixathon.
In contrast, three patients (1.5%) had cerebrovascular events in the CHOP group, all of which occurred during the follow-up period.
Nasprotno pa so se cerebrovaskularni dogodki pojavili pri treh bolnikih (1,5 %) v skupini CHOP, vsi med obdobjem spremljanja.
Rixathon is usually taken together with another medicine called methotrexate.
Rixathon se običajno jemlje skupaj z zdravilom, imenovanim metotreksat.
How much and how often you will receive your treatment a) If you are being treated for non-Hodgkin's Lymphoma
Koliko zdravila boste dobili in kako pogosto a) Če se zdravite zaradi ne-Hodgkinovega limfoma
Before giving a subsequent course of Rixathon treatment, patients should be re-evaluated for any potential risk for infections.
Pred dajanjem nadaljnjega cikla zdravila Rixathon je treba bolnike ponovno oceniti glede možnega tveganja za okužbe.
The HCP Alert card addressing the correct use of Rixathon contains the following key elements: - The advice that Rixathon is for intravenous use only and recommendations how to ensure this route of administration
Opozorilna kartica za zdravstvenega delavca, ki obravnava pravilno uporabo zdravila Rixathon, vsebuje naslednje ključne vsebine: - navedbo, da je zdravilo Rixathon namenjeno samo za intravensko uporabo, in priporočila, kako zagotoviti, da se uporablja ta pot uporabe
Data from extended follow up of patients in the study (median follow-up 9 years) confirmed the longterm benefit of rituximab maintenance therapy in terms of PFS, EFS, TNLT, and TNCT (Table 7).
Podatki iz podaljšanega spremljanja bolnikov v študiji (mediana spremljanja 9 let) so potrdili dolgoročno korist vzdrževalnega zdravljenja z rituksimabom glede na PFS, EFS, TNLT in TNCT
The ADRs identified only during post-marketing surveillance, and for which a frequency could not be estimated, are listed under “not known”.
Neželeni učinki, ki so jih opazili samo po prihodu zdravila na trg in za katere pogostnosti ni mogoče oceniti, so navedeni v „neznana“.
Mild or moderate infusion-related reactions (IRR) (section 4.8) usually respond to a reduction in the rate of infusion.
Blage ali zmerne reakcije, povezane z infuzijo (poglavje 4.8), lahko običajno zmanjšamo z manjšim infuzijskim pretokom.
• taste problems - such as changes in the way things taste
• motnje okušanja - na primer spremenjen okus stvari,
Rixathon is indicated in adults for the following indications:
Zdravilo Rixathon je pri odraslih indicirano za naslednje indikacije:
Rixathon should be administered under the close supervision of an experienced healthcare professional, and in an environment where full resuscitation facilities are immediately available (see section 4.4).
Zdravilo Rixathon je treba dajati pod nadzorom izkušenega zdravnika in v okolju, kjer so vsi pripomočki za oživljanje nemudoma na voljo (glejte poglavje 4.4).
This antigen does not internalise upon antibody binding and is not shed from the cell surface.
Po vezavi s protitelesom ne vstopa v notranjost celice, niti se ne odcepi s celične površine.
The primary objective for the study was complete remission (complete epithelialisation and absence of new and/or established lesions) at month 24 without the use of prednisone therapy for two months or more (CRoff for ≥2 months).
Primarni cilj študije je bila popolna remisija (CR - complete remission) (popolna epitelizacija in odsotnost novih in/ali razvitih lezij) po 24 mesecih brez uporabe prednizonskega zdravljenja v obdobju dveh mesecev ali več (CRoff za ≥ 2 meseca).
Figure 1: Change from baseline of DAS28-ESR by baseline autoantibody status
Slika 1: Sprememba v DAS28-ESR od izhodišča glede na izhodiščno stanje protiteles
Your doctor will check if you should have any vaccines before you receive Rixathon.
Vaš zdravnik bo preveril, ali bi morali biti cepljeni, preden boste dobili zdravilo Rixathon.
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Rixathon slows down the damage to your joints caused by rheumatoid arthritis and improves your ability to do normal daily activities.
Zdravilo Rixathon upočasni nastanek okvar sklepov, ki so posledica revmatoidnega artritisa, ter izboljša vašo sposobnost za opravljanje običajnih dnevnih aktivnosti.
Table 16 Percentage of patients who achieved complete remission at 6 months (intent-to-treat population*)
Odstotek bolnikov, ki so po 6 mesecih dosegli popolno remisijo (populacija, ki so jo nameravali zdraviti*)
• tight or painful muscles
• napete ali boleče mišice,
Patients with CLL have too many abnormal lymphocytes, which accumulate mainly in the bone marrow and blood.
Bolniki s KLL imajo preveč nenormalnih limfocitov, ki se kopičijo predvsem v kostnem mozgu in krvi.
Treatment with rituximab in combination with methotrexate over multiple courses resulted in sustained improvements in the clinical signs and symptoms of RA, as indicated by ACR, DAS28-ESR and EULAR responses which was evident in all patient populations studied (Figure 2).
Zdravljenje z rituksimabom v kombinaciji z metotreksatom v več ciklih je prineslo stalno izboljšanje kliničnih znakov in simptomov RA, kot so pokazali odzivi po ACR, DAS28-ESR in EULAR; to je bilo opazno v vseh raziskovanih populacijah bolnikov (slika 2).
Seropositive patients also had a significantly greater decrease in DAS28-ESR compared to seronegative patients (Figure 1).
Seropozitivni bolniki so imeli tudi značilno večje zmanjšanje v DAS28ESR kot seronegativni bolniki (slika 1).
In a long-term observational safety study, 97 GPA/MPA patients received treatment with rituximab (mean of 8 infusions [range 1-28]) for up to 4 years, according to their physician's standard practice and discretion.
V dolgoročni opazovalni študiji varnosti je 97 bolnikov z GPA/MPA prejemalo zdravljenje z rituksimabom (v povprečju 8 infuzij [razpon od 1 do 28]) do 4 leta, v skladu s standardno prakso in presojo njihovega zdravnika.
In patients where the treatment is working, Rixathon may be used as a maintenance treatment for 2 years after completing the initial treatment.
Pri bolnikih, pri katerih takšno zdravljenje deluje, je mogoče zdravilo Rixathon uporabljati kot vzdrževalno zdravljenje še dve leti po dokončanju začetnega zdravljenja.
• If you respond well to treatment, you may be given Rixathon as a maintenance treatment every 2 or 3 months for two years.
• Če se boste dobro odzvali na zdravljenje, boste lahko zdravilo Rixathon dobivali kot vzdrževalno zdravljenje na dva meseca ali tri, in sicer dve leti.
A small proportion of patients had prolonged peripheral B cell depletion lasting 2 years or more after their last dose of rituximab.
Pri majhnem deležu bolnikov je bil upad števila perifernih celic B dolgotrajen, trajal je 2 leti ali več po zadnjem odmerku rituksimaba.
9.25 years
9,25 let
The proportion of patients experiencing an infusionrelated reaction was 29% (11 patients), 40% (15 patients), 13% (5 patients), and 10% (4 patients) following the first, second, third, and fourth infusions, respectively.
Delež bolnikov, ki se jim je pojavila z infundiranjem povezana reakcija, je bil po prvem infundiranju 29 % (11 bolnikov), po drugem 40 % (15 bolnikov), po tretjem 13 % (5 bolnikov) in po četrtem 10 % (4 bolniki).
GLSG'00 CHOP, 205 R-CHOP, 223 18
CHOP: 205 R-CHOP: 223
This should be followed by oral prednisone 1 mg/kg/day (not to exceed 80 mg/day, and tapered as rapidly as possible based on clinical need) during and after the 4 week induction course of Rixathon treatment.
1 mg/kg/dan prednizona peroralno (odmerek ne sme preseči 80 mg/dan in ga je treba zmanjšati, kolikor hitro je mogoče glede na klinične potrebe) med in po 4-tedenskem indukcijskem zdravljenju z zdravilom Rixathon.
• raised blood pressure
• zvišan krvni tlak,
2 Frequency category derived from post-marketing data.
2Pogostnost pridobljena iz podatkov pridobljenih po prihodu zdravila na trg.
The majority of patients (81%) showed signs of B cell return, with counts > 10 cells/μL by month 12, increasing to 87% of patients by month 18.
Pri večini bolnikov (81 %) se je število celic B ponovno povečalo na > 10 celic/µl do 12. meseca, do 18. meseca pa še pri večjem, 87-% deležu bolnikov.
Mean change in SF-36 PHS
Povprečna sprememba SF-36 PHS
Of the patients originally receiving methotrexate alone, 81% received rituximab either as rescue between weeks 16-24 or in the extension trial, before week 56.
Od bolnikov, ki so prvotno dobivali samo metotreksat, jih je 81 % dobilo rituksimab kot rešilno zdravilo (rescue) med 16. in 24. tednom ali v okviru nadaljevalne študije pred 56. tednom.
If a patient develops PML, the dosing of Rixathon must be permanently discontinued.
Če se pri bolniku razvije PML, je treba uporabo zdravila Rixathon dokončno ukiniti.
Number of responders (response rate [%]) ap-value is from Fisher's exact test with mid-p correction b 95% confidence interval is corrected Newcombe interval
Število odzivnih (delež odziva [%]) a Vrednost p je vrednost iz Fisherjevega eksaktnega testa s sredinskim popravkom p. b 95-% interval zaupanja je korigiran Newcombov interval.
The cells that are affected by Rixathon help to fight infection and you should wait until the infection has passed before you are given Rixathon.
Celice, ki jih zdravilo Rixathon uniči, pomagajo pri borbi proti okužbam, zato morate počakati, da se okužba pozdravi, preden prejmete zdravilo Rixathon.
If you respond well to treatment, you may be given Rixathon as a maintenance treatment.
Če se boste na zdravilo dobro odzvali, boste lahko zdravilo Rixathon prejemali kot vzdrževalno zdravljenje.
During the treatment period (induction treatment phase comprising of R-CHOP for at most eight cycles), four patients (2%) treated with R-CHOP, all with cardiovascular risk factors, experienced thromboembolic cerebrovascular accidents during the first treatment cycle.
Med obdobjem zdravljenja (faza indukcijskega zdravljenja, ki je obsegalo R-CHOP vsaj osem ciklov) so se pri štirih bolnikih (2 %), zdravljenih z R-CHOP, ki so vsi imeli kardiovaskularne dejavnike tveganja, med prvim ciklom zdravljenja pojavili trombembolični cerebrovaskularni dogodki.
The highest intravenous dose of rituximab tested in humans to date is 5,000 mg (2,250 mg/m²), tested in a dose escalation study in patients with chronic lymphocytic leukaemia.
Največji do zdaj preizkušen intravenski odmerek rituksimaba pri človeku je 5.000 mg (2.250 mg/m2), preizkušen v študiji povečevanja odmerka pri bolnikih s kronično limfocitno levkemijo.
Rituximab is not indicated for these patients, since the safety data about long-term rituximab treatment are insufficient, in particular concerning the risk of development of malignancies and PML.
Rituksimab ni indiciran za uporabo pri teh bolnikih zaradi nezadostnih podatkov o varnosti dolgoročnega zdravljenja z rituksimabom, še posebej v zvezi s tveganjem za razvoj malignih bolezni ter PML.
At week 24, patients who were seropositive to RF and/or anti-CCP at baseline had a significantly increased probability of achieving ACR20 and 50 responses compared to seronegative patients (p=0.0312 and p=0.0096) (Table 15).
Po 24 tednih so imeli bolniki, ki so bili izhodiščno seropozitivni za RF in/ali anti-CCP, značilno večjo verjetnost, da dosežejo odziv ACR20 in 50, v primerjavi s seronegativnimi bolniki (p = 0,0312 in p = 0,0096) (preglednica 15).
This is mostly accounted for by IRRs (most frequent during the first treatment course), RA exacerbation and infections, all of which were more frequent in the first 6 months of treatment.
To gre v glavnem pripisati reakcijam, povezanim z infuzijo (ki se najpogosteje pojavljajo v prvem ciklu zdravljenja), poslabšanju revmatoidnega artritisa in okužbam; vse našteto se je pogosteje pojavljalo v prvih 6 mesecih zdravljenja.
10.49 years
10,49 let
Patients were between 19 and 79 years of age and had not received prior therapies for pemphigus.
19 do 79 let in predhodno niso prejemali zdravljenja za pemfigus.
This is because there is not much information about the use of rituximab in children and young people.
O uporabi rituksimaba pri otrocih in mladostnikih namreč ni veliko informacij.
The incidence of thrombocytopenia was low (< 1%, grade 3/4) and was not different between treatment arms.
Incidenca trombocitopenije je bila nizka (< 1 % 3. ali 4. stopnje) in se med zdravljenima skupinama ni razlikovala.
Initiate at a rate of 250 mg/hour for the first 30 minutes and then 600 mg/hour for the next 90 minutes.
Začetna hitrost infundiranja je 250 mg/h prvih 30 minut in nato 600 mg/h naslednjih 90 minut.
Based on the mechanism of action of rituximab and the knowledge that B cells play an important role in maintaining normal immune response, patients have an increased risk of infection following rituximab therapy (see section 5.1).
Glede na mehanizem delovanja rituksimaba in dejstvo, da imajo celice B pomembno vlogo pri vzdrževanju normalnega imunskega odziva, imajo lahko bolniki, ki se zdravijo z rituksimabom, povečano tveganje za okužbe (glejte poglavje 5.1).
B lymphocytes are involved in the cause of some of the symptoms you have.
Limfociti B sodelujejo pri nastanku nekaterih simptomov, ki jih imate.
Rituximab N=505
rituksimab n = 505